Unió Europea - islandès - EMA (European Medicines Agency)

eli lilly and company limited - spinosad, milbemycin oxím - sníklaeyðandi vörur, skordýraeitur og repellents, endectocides - hundar - fyrir meðferð og koma í veg fló (ctenocephalides sus) sníkjudýra í hunda þar einn eða fleiri eftir vísbendingar þarf samtímis: fyrirbyggja heartworm sjúkdómur (l3, l4 dirofilaria immltís);fyrirbyggja angiostrongylosis með því að draga úr stig af sýkingu með óþroskaður fullorðinn (l5) angiostrongylus vasorum;meðferð maga þráðormurinn sýkingar af völdum lögð (l4, óþroskaður fullorðinn, l5) og fullorðinn ancylostoma caninum), roundworms (óþroskaður fullorðinn l5, og fullorðinn toxocara canis og fullorðinn toxascaris andreoletti) og whipworm (fullorðinn trichuris vulpis).

Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

animedica gmbh* - enrofloxacinum inn - tafla - 150 mg

Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

animedica gmbh* - enrofloxacinum inn - tafla - 50 mg

Unió Europea - islandès - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - eitilfrumukrabbamein, mantle-cell - Æxlishemjandi lyf - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Unió Europea - islandès - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - Önnur lyf í taugakerfinu - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

livisto int'l, s.l. - firocoxibum inn - tuggutafla - 227 mg

Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

livisto int'l, s.l. - firocoxibum inn - tuggutafla - 57 mg

Unió Europea - islandès - EMA (European Medicines Agency)

servier (ireland) industries ltd - agomelatine - Þunglyndi, major - psychoanaleptics, - meðferð við alvarlegum þunglyndisþáttum hjá fullorðnum.

Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

animedica gmbh* - chlortetracycline hydrochloride - húðúði, dreifa - 2,45 % w/w

Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

vetcare oy - benzylpenicillinprocainum - spenalyf, dreifa - 600 mg